• Monitoring newly launched and emerging clinical trials in non-small cell lung cancer (NSCLC)

• Tracking guideline updates and evolving standards of care in lung cancer

• Identifying key developments in biomarker-driven and precision oncology

• Following advances in targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs)

• Analyzing competitive activity across major pharmaceutical and biotechnology companies

• Highlighting trends in clinical development, regulatory milestones, and treatment innovation

• Providing actionable intelligence on the rapidly evolving NSCLC landscape

• Translating complex oncology developments into concise insights for healthcare stakeholders

This bi-annual report is intended for our biotech clients. Questions addressed in our Medical Affairs Opportunity Assessments reports are: 1) What evidence will be (is still) needed)?; 2) What MSL structure is required?; and 3) What KOL engagement strategy makes sense?

One-page monthly reports for leaders. This format includes trends, drivers, business implications, and recommended actions.